Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Branaplam in Early Manifest Huntington's Disease
NCT05111249Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of branaplam in Huntington's disease (HD), sponsored by Novartis. Primary endpoints: Percentage Change From Baseline in mHTT Protein in CSF at 17 weeks and Number of Participants With Adverse Events and Serious Adverse Events at 69 weeks. Started Dec 2021; status: terminated.
02
Drugs
branaplam
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT05111249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111249.